Table 9 Novel agents in clinical trial phase III studies for first-line and second-line treatment of DLBCL-NOS
Drug | Agent mechanism or target | Pathway | Manufacturer | Status | Studies |
|---|---|---|---|---|---|
Enzastaurin (LY317615) | PKCβ inhibitor | (↓) BCR/ NF-κB pro-survival signaling | Denovo Biopharma LLC | Completed phase III | [258] Trial-No: NCT00332202 (PRELUDE) |
Ofatumumab (Arzerra) | CD20 Second- generation anti-CD20 mAb | (↓) CD20 pro-survival signaling | GSK Genmab | Completed phase III | Trial-No:NCT01014208 (ORCHARRD) |
Bortezomib (Velcade) | Proteasome Inhibitor | (↓) NF-κB pro-survival signaling | Millennium Pharmaceuticals | Ongoing phase III | Trial-No: NCT01805557 (FILVERAL12) NCT01324596 (REMoDL-B) |
Lenalidomide (Revlimid) | IRF4 Immuno modulatory drug | (↓) BCR/ NF-κB pro-survival signaling (↑) pro-apoptotic STAT2-IFNα/β axis | Celgene | Ongoing phase III | [294] Trial-No: NCT01122472 (REMARC) NCT02285062 (ROBUST) NCT02128061 NCT01197560 |
Ibrutinib (PCI-32765) | BTK inhibitor | (↓) BCR/ NF-κB pro-survival signaling | Pharmacyclics Janssen Pharmaceutica | Ongoing phase III | Trial-No: NCT01804686 NCT01855750 |
Everolimus (RAD001/Afinitor) | mTORC1 inhibitor | (↓) PIK/AKT/ mTORC1 pro-survival signaling | Novartis Pharmaceuticals | Ongoing phase III | Trial-No: NCT00790036 |
Obinutuzumab (Gazyva, Gazyvaro GA101/RO5072759) | CD20 Third- generation anti-CD20 mAb | (↓) CD20 pro-survival signaling | Roche Pharmaceuticals | Ongoing phase III | Trial-No: NCT01287741 (GOYA) |